Stepan (SCL) Stock Shrugs Off Q3 Earnings As Margins Rebuild

Stepan just posted its Q3 2026 scorecard and the first verdict from traders was a shrug. The stock slipped only 0.5% to about $69.60 by Friday’s close, even as the quarter put a sharp spotlight on margin repair.

For a specialty chemicals producer that lives and dies on the spread between input costs and selling prices, the headline was clear. Adjusted EBITDA reached $66.3m and adjusted earnings per share came in at $0.94, both pointing to a business working hard to rebuild profitability even if the share price barely flinched.

Like the margin story at Stepan but want a cleaner balance of pricing power and profitability right now? Check out our list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): US$692.2m vs. US$590.3m (higher year on year)
• Net Income, excl. extra items (Q3 2026 vs Q3 2025): US$17.8m vs. US$10.8m (higher year on year)
• Basic EPS (Q3 2026 vs Q3 2025): US$0.78 vs. US$0.47 (higher year on year)
• Adjusted EBITDA (Q3 2026 vs Q3 2025): US$66.3m vs. the prior-year Q3 level (management reported an 18% year on year increase)

Tired of scrolling through paragraphs of earnings commentary and raw figures to piece together what Stepan is really doing on profitability? Get the full visual picture of Stepan's margins and broader financial profile in an easy dashboard view with our company report for Stepan.

Stepan bull case hinges on cost reset proof

The upbeat view says Stepan can turn Project Catalyst and Pasadena into a tangible earnings upgrade, not just a nice story.

"Ongoing Project Catalyst actions, including site closures such as Fieldsboro and asset decommissioning in Millsdale and Stalybridge, together with targeted salaried headcount and procurement efficiencies, are expected to support the approximately US$100 million pretax savings plan over two years and could reset Stepan’s cost base in a way that benefits earnings quality and margins."

Q3 shows that thesis gaining traction. Adjusted EBITDA rose 18% and adjusted EPS nearly doubled while organic volume increased 7%. Catalyst savings are running ahead of plan and management now expects US$66m to US$70m of the US$100m target in 2026.

Bear case tests Pasadena and execution risk at Stepan

The cautionary view argues that capacity adds and restructuring could stumble, leaving Stepan with cost and complexity rather than better economics.

"The main requirement for the strategy to work as intended is that Stepan continues to execute on Project Catalyst and the Pasadena alkoxylation facility ramp, so that site closures, asset moves, and new capacity translate into the targeted cost savings and specialty volume growth."

Recent numbers give that concern less bite but do not erase it. Organic volume rose across all segments and Pasadena is described as ahead of its tolling savings plan. Project Catalyst savings hit a US$23m run rate in Q3 and are tracking above the original 2026 goal, which points to progress rather than slippage so far.

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for.

Hunt For Mispriced Earnings Power

Stepan shows how quarterly headlines and share price reactions can quickly diverge. The real opportunity could sit in stocks the market has not fully rewarded yet.

• Company 1 - 41% below our estimate - builds composite access mats utilities rent as they accelerate long duration grid and pipeline projects.
• Company 2 - 38% below our estimate - expands coconut based drinks as retailers add private label lines alongside established branded shelf space.
• Company 3 - 48% below our estimate - co-designs hardware for medical, automotive and factory customers that now want partners embedded from prototype stage.

Those are three of them. See all 30 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com